Evreux M
Gastro-Enterology Department, Hotel-Dieu, Lyon, France.
Am J Med. 1987 Sep 28;83(3B):48-50. doi: 10.1016/0002-9343(87)90827-8.
Fifty patients in whom endoscopy revealed peptic esophagitis were included in a double-blind study in which either sucralfate (1 g four times a day) or an alginate/antacid compound (5 g four times a day) were randomly assigned. After six weeks of treatment, efficacy and clinical safety were evaluated in 23 patients in the sucralfate group and 22 patients in the alginate/antacid group. No significant difference between the two treatments was detected with regard to efficacy, evaluated on the basis of clinical and endoscopic criteria. Clinical safety was also good in both groups. Sucralfate was, therefore, found to be as effective and as well tolerated as the alginate/antacid compound in the treatment of peptic esophagitis.
50例经内镜检查显示患有消化性食管炎的患者被纳入一项双盲研究，在该研究中，患者被随机分配接受硫糖铝（每日4次，每次1克）或藻酸盐/抗酸剂复合物（每日4次，每次5克）治疗。治疗六周后，对硫糖铝组的23例患者和藻酸盐/抗酸剂组的22例患者进行了疗效和临床安全性评估。根据临床和内镜标准评估疗效，结果发现两种治疗方法之间没有显著差异。两组的临床安全性也都良好。因此，发现硫糖铝在治疗消化性食管炎方面与藻酸盐/抗酸剂复合物一样有效且耐受性良好。
